Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
Date:5/3/2010

LYNBROOK, N.Y., May 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30am EDT on Friday, May 7, 2010 to report its first quarter 2010 financial results and corporate highlights.

To participate in the call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=68879.

A replay of the call will be available one hour after the conference call ends on May 7, 2010 until 9:00am EDT on May 14, 2010. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 440390. The archived webcast will be available for 90 days in the Investor Relations section of the BioSpecifics website at http://www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium has gained approval of XIAFLEX by the FDA in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about the company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium regarding XIAFLEX as a major breakthrough for patients with Dupuytren's contracture; the distribution network for XIAFLEX; the number of patients with Dupuytren's contracture in the United States; the ability to obtain regulatory approval of XIAFLEX™ in the United States for Peyronie's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX™ in its territory for Dupuytren's contracture and Peyronie's disease, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech, Inc. and its affiliates; whether Auxilium exercises its option under the Company's license and development agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2009 filed with the SEC. There may be additional risks that BioSpecifics does not presently know or that BioSpecifics currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... 2017 Kohll,s Pharmacy & Homecare is the first distributor ... States . The Raizer is a simple battery operated ... to an almost-standing position within a few minutes. ... assistant and does not require any extra effort besides ... child can operate it, and lightweight and portable ...
(Date:5/30/2017)... CAESAREA, Israel , May 30, 2017 DarioHealth Corp. ... and big data solutions, today announced that it will be presenting ... 2017, at 8:00 AM PT. Erez Raphael , CEO, of ... The conference will be held on June 6th & 7th, ... 180 companies in the small / micro-cap space. ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... , President and CEO, will represent the Company in a ... Healthcare Conference on Tuesday, June 13, 2017 at 10:40 a.m. ... at Terranea Resort in Rancho Palos Verdes, CA. ... for the event will be available on the Company,s website ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... Fresenius Vascular Care, a national network of outpatient vascular care and ambulatory ... range of vascular conditions, has today announced its new name, Azura Vascular Care, as ... than 40 local brands, a phased rollout of the new brand across all locations ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that the introduction of school choice can promote economic development in economically distressed ... that has, according to the report, contributed to the economic development of the ...
(Date:6/20/2017)... ... ... AMC Health , the leading provider of proven real-time virtual care ... to its approach in demonstrating positive outcomes in the healthcare market, AMC Health has ... of eVisits to support virtual studies. , In a study concluded this ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn ... with the VATECH PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, ... place dental implants precisely and restore oral health for those who are missing ...
(Date:6/20/2017)... ... 20, 2017 , ... As a leading dental practice, Wall Centre Dental supports ... disease. Those with bleeding gums in Vancouver, BC, may be developing gingivitis, the first ... heart disease, stroke and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer ...
Breaking Medicine News(10 mins):